Anavex Life Sciences
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2006-01-01
- Employees
- 40
- Market Cap
- $515.5M
- Website
- http://www.anavex.com
- Introduction
Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.
Earnings call transcript: Anavex Life Sciences Q4 2024 beats EPS forecast
Anavex Life Sciences reported Q4 2024 EPS of -$0.14, beating forecasts of -$0.1567. The stock surged 17.24% on positive investor sentiment. The company's progress in Alzheimer's and schizophrenia treatments, including EMA's acceptance of Blakamizant's marketing application, contributed to the strong performance.
Anavex Life Sciences Corp. (AVXL) reports earnings
Anavex Life Sciences Corp. filed its Form 10-K detailing ongoing development of CNS therapeutics, including Alzheimer's, Parkinson's, and Rett syndrome. The company reported a net loss of $43.0 million, down from $47.5 million, due to reduced R&D expenses. Cash and equivalents stood at $132.2 million, with $110.8 million available under a stock purchase agreement. Anavex is advancing its clinical programs and addressing legal proceedings.
ANAVEX LIFE SCIENCES CORP. SEC 10-K Report
Anavex Life Sciences Corp. released its annual Form 10-K report, detailing financial performance with decreased operating expenses and net loss, and business highlights including ongoing clinical trials for Alzheimer's, Parkinson's, and Rett syndrome. The company faces financial and operational risks, regulatory challenges, and a competitive landscape in the biotechnology sector.
Anavex Sciences Soars On Earnings Relief, EU Filing Acceptance For Alzheimer's Drug
Anavex Life Sciences Corp. shares surged 27%, reaching their highest since Feb 2023, driven by positive earnings and EMA's acceptance of blarcamesine's MAA for Alzheimer's. The company reported a narrower-than-expected Q4 loss and strong cash reserves. Retail investors on Stocktwits celebrated, shifting sentiment to 'bullish'.
Anavex Life Sciences Corp. (AVXL) Q4 2024 Earnings Call Transcript
Anavex Life Sciences Corp. Q4 2024 earnings call on Dec 23, 2024, hosted by Clint Tomlinson. Participants include Christopher Missling, President and CEO, and Sandra Boenisch, Principal Financial Officer. The call includes projections and forward-looking statements, cautioning risks and uncertainties. Missling thanks attendees and wishes a Merry Christmas and Happy New Year.
Blarcamesine Receives EMA Filing Acceptance for Treatment of Alzheimer's Disease
Blarcamesine, an oral Alzheimer’s treatment, demonstrated efficacy in slowing clinical decline in early Alzheimer’s patients, with a favorable safety profile. The European Medicines Agency accepted Anavex Life Sciences' Marketing Authorization Application for review.
Anavex Life Sciences Reports Fiscal 2024 Fourth Quarter
Anavex Life Sciences reported Q4 and FY 2024 financials, highlighting progress in Alzheimer's treatment with blarcamesine. The company anticipates a 4-year cash runway and reported a Q4 net loss of $11.6M.
© Copyright 2025. All Rights Reserved by MedPath